Co-suppression of MDR1 (multidrug resistence 1) and GCS (glucosylceramide synthase) restores sensitivity to mutidrug resistance breast cancer cells by RNA interference (RNAi)

Cancer Biology and Therapy

Volumn 8, Issue 12, 2009, Pages 1117-1121

  Zhang, Xiaofang ^a   Li, Juan ^a   Qiu, Zhengang ^b   Gao, Peng ^a   Wu, Xiaojuan ^a   Zhou, Genyin ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Breast cancer; Ceramide; Glucosylceramide synthase; MDR; MDR1; P glycoprotein; RNA interference

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

EID: 68049140754     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.12.8374     Document Type: Article

References (26)

1. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 1987; 84:3004-8.
2. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of Pglycoprotein. Cancer Chemother Pharmacol 1997; 40:13-9.
3. Gao P, Zhou GY, Lei DP, Zhang XF, Li L, Xu JW, et al. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Cytotherapy 2007; 9:795-801.
4. Nadali F, Pourfathollah AA, Alimoghaddam K, Nikougoftar M, Rostami S, Dizaji A, et al. Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology 2007; 12:393-401.
5. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996; 271:19530-6.
6. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 1998; 18:475-80.
7. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999; 274:1140-6.
8. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 2000; 275:7138-43.
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
10. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Let 2003; 545:144-50.
11. Zhao LJ, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 2003; 316:137-41.
12. Li CB, Zhang F, Shi YR, Wei XY, Yang Y, Niu RF. Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA. Ai Zheng 2004; 23:1605-10.
13. Sun YL, Zhou GY, Li KN, Gao P, Zhang QH, Zhen JH, et al. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma 2006; 53:1-8.
14. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-14.
15. Gao P, Zhou GY, Guo LL, Zhang QH, Zhen JH, Fang AJ, et al. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Lett 2007; 256:81-9.
16. Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang HA, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004; 3:633-9.
17. Kaszubiak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes 2007; 31:419-30.
18. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, Kok JW. MRP1 and glucosylceramide are coordinately overexpressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 2004; 110:511-22.
19. Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H, et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002; 16:1111-3.
20. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002; 1:205-13.
21. Gouazé V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade downregulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005; 65:3861-7.
22. Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002; 5:349-55.
23. Norris-Cervetto E, Callaghan R, Platt FM, Dwek RA, Butters TD. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J Biol Chem 2004; 279:40412-8.
24. Joli F, Bouchemal N, Laigle A, Hartmann B, Hantz E. Solution structure of a purine rich hexaloop hairpin belonging to PGY/MDR1 mRNA and targeted by antisense oligonucleotides. Nucleic Acids Res 2006; 34:5740-51.
25. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5:39-47.
26. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545:144-50.